# US 2013/0274122 A1 · Assay for chlamydia trachomatis by amplification and detection of chlamydia trachomatis pmpa gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274122 A1
- Document ID: US20130274122A1
- Status: Published application
- Kind: A1
- Application number: 13/786,994
- Filed: 2013-03-06
- Published: 2013-10-17
- Earliest claimed: 2008-10-27
- Assignees: Becton, Dickinson and Company
- Applicants: Becton, Dickinson and Company
- Inventors: Courtney E. Maus; Jason P. Stevens; Danielle Koffenberger
- Web page: https://patentgrep.com/patent/US20130274122A1

## CPC

- C12Q 1/689: for bacteria
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A region of the Chlamydia trachomatis pmpA gene has been identified which is useful for performing amplification assays to determine specifically whether C. trachomatis is present in the sample being tested. Oligonucleotides useful for detecting this gene by performing the polymerase chain reaction (PCR) are disclosed. The disclosed oligonucleotides can be used in an assay which is specific for multiple strains or serovars of C. trachomatis, including the variant E serovar, and which does not show cross reactivity with the genomes of other microorganisms or with human DNA. In addition, the disclosed oligonucleotides can be used to in a multiplex system. This invention also contemplates a kit including oligonucleotides, and optionally other reagents, for the detection of C. trachomatis using PCR.

## Claims

### Claim 1

A method for detecting Chlamydia trachomatis in a biological sample comprising:
providing a biological sample;
contacting the biological sample with a substance comprising an oligonucleotide set that comprises at least one oligonucleotide probe that is detectably labeled and has a nucleotide sequence length of about 10 to about 50 and at least two oligonucleotide primers each having a nucleotide sequence length of about 10 to about 150, under conditions such that the probes and primers anneal to SEQ ID NO:2 at the location between about base pairs 1835-2176 of the pmpA gene;
wherein the probe comprises a sequence selected from the group consisting of SEQ ID NO:12, SEQ ID NO:15 and oligonucleotide sequences that are at least 70% homologous to SEQ ID NO:12, and SEQ ID NO:15 and the primers comprise oligonucleotide sequences selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:16 and oligonucleotide sequences that are at least 70% homologous to SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:16;
amplifying the target sequence between the two primers using polymerase chain reaction; and
detecting the label as an indication of the hybridization of the probe set to the target sequence thereby indicating the presence or amount of Chlamydia trachomatis in the biological sample.

### Claim 2 (depends on 1)

The method of claim 1 wherein, the oligonucleotide set comprises a probe comprising a sequence selected from the group consisting of SEQ ID NO:12 and SEQ ID NO:15 and oligonucleotide sequences that are at least 80% homologous to SEQ ID NO:12 and SEQ ID NO:15.

### Claim 3 (depends on 1)

The method of claim 1, wherein the oligonucleotide set comprises a probe comprising a sequence selected from the group consisting of SEQ ID NO:12, SEQ ID NO:15 and oligonucleotide sequences that are at least 90% homologous to SEQ ID NO:12 and SEQ ID NO:15.

### Claim 4 (depends on 1)

The method of claim 1, wherein the oligonucleotide primers comprises at least two primers comprising sequences selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:16 and oligonucleotide sequences that are at least 80% homologous to SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:16.

### Claim 5 (depends on 1)

The method of claim 1, wherein the oligonucleotide primers comprises at least two primers comprising sequences selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:16 and oligonucleotide sequences that are at least 90% homologous to SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:16.

### Claim 6 (depends on 1)

The method of claim 1, wherein the oligonucleotide set is selected from the group consisting of a first oligonucleotide set comprising oligonucleotide primers having an oligonucleotide sequence comprising SEQ ID NO:10 and SEQ ID NO:11 and an oligonucleotide probe having an oligonucleotide sequence comprising SEQ ID No:12; a second oligonucleotide set comprising oligonucleotide primers having an oligonucleotide sequence comprising SEQ ID NO:13 and SEQ ID NO:14 and an oligonucleotide probe having an oligonucleotide sequence comprising SEQ ID NO:15; and a third oligonucleotide set comprising oligonucleotide primers having an oligonucleotide sequence comprising SEQ ID NO:13 and SEQ ID NO:16 and an oligonucleotide probe having an oligonucleotide sequence comprising SEQ ID NO:15.

### Claim 7 (depends on 1)

The method of claim 1, wherein the oligonucleotide primers are selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, and oligonucleotide sequences that are at least 70% homologous to SEQ ID NO:10 and SEQ ID NO:11; and the oligonucleotide probe is selected from the group consisting of SEQ ID No:12 and oligonucleotide sequences that are at least 70% homologous to SEQ ID NO:12.

### Claim 8 (depends on 7)

The method of claim 7, wherein the oligonucleotide primers consist of SEQ ID NO:10 and SEQ ID NO:11, and the oligonucleotide probe consists of SEQ ID NO:12.

### Claim 9 (depends on 1)

The method of claim 1, wherein the probes and primers anneal to SEQ ID NO:2 at the location between about base pairs 1966-2073 of the pmpA gene.

### Claim 10 (depends on 1)

The method of claim 1, wherein the detectable label is a fluorescence marker.

### Claim 11 (depends on 1)

The method of claim 1, wherein the polymerase chain reaction is real-time polymerase chain reaction.

### Claim 12 (depends on 1)

The method of claim 1, wherein the method is performed in a multi-plex platform.

### Claim 13

An oligonucleotide set for the detection of the pmpA gene of Chlamydia trachomatis in a biological sample comprising at least one oligonucleotide probe that is detectably labeled and has a nucleotide sequence length of about 10 to about 50, and at least two oligonucleotide primers, each of which has a nucleotide sequence length of about 10 to about 150,
wherein the probes and primers target the nucleotides of SEQ ID NO:2 at the location between about base pairs 1835-2176 of the pmpA gene;
wherein the at least one probe comprises a sequence selected from the group consisting of SEQ ID NO:12, SEQ ID NO:15 and oligonucleotide sequences that are at least 70% homologous to SEQ ID NO:12, and SEQ ID NO:15 and the at least two primers comprise oligonucleotide sequences selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:16 and oligonucleotide sequences that are at least 70% homologous to SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:16.

### Claim 14 (depends on 13)

The oligonucleotide set of claim 13, wherein the at least one probe comprises a sequence selected from the group consisting of SEQ ID NO:12 and SEQ ID NO:15 and oligonucleotide sequences that are at least 80% homologous to SEQ ID NO:12 and SEQ ID NO:15.

### Claim 15 (depends on 13)

The oligonucleotide set of claim 13, wherein the at least one probe comprises a sequence selected from the group consisting of SEQ ID NO:12, SEQ ID NO:15 and oligonucleotide sequences that are at least 90% homologous to SEQ ID NO:12 and SEQ ID NO:15.

### Claim 16 (depends on 13)

The oligonucleotide set of claim 13, wherein the at least two primers comprise sequences selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:16 and oligonucleotide sequences that are at least 80% homologous to SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:16.

### Claim 17 (depends on 13)

The oligonucleotide set of claim 13, wherein the at least two primers comprising sequences selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:16 and oligonucleotide sequences that are at least 90% homologous to SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:16.

### Claim 18 (depends on 13)

The oligonucleotide set of claim 13, wherein the oligonucleotide set is selected from the group consisting of a first oligonucleotide set comprising oligonucleotide primers having an oligonucleotide sequence comprising SEQ ID NO:10 and SEQ ID NO:11 and an oligonucleotide probe having an oligonucleotide sequence comprising SEQ ID No:12, a second oligonucleotide set comprising oligonucleotide primers having an oligonucleotide sequence comprising SEQ ID NO:13 and SEQ ID NO:14 and an oligonucleotide probe having an oligonucleotide sequence comprising SEQ ID NO:15 and a third oligonucleotide set comprising oligonucleotide primers having an oligonucleotide sequence comprising SEQ ID NO:13 and SEQ ID NO:16 and an oligonucleotide probe having an oligonucleotide sequence comprising SEQ ID NO:15.

### Claim 19 (depends on 18)

The oligonucleotide set of claim 18, wherein the oligonucleotide primers consist of SEQ ID NO:10 and SEQ ID NO:11, and the oligonucleotide probe consists of SEQ ID NO:12.

### Claim 20 (depends on 13)

The oligonucleotide set of claim 13, wherein the primers and probes target the nucleotides of SEQ ID NO:2 at the location between about base pairs 1966-2073 on the pmpA gene.

### Claim 21 (depends on 13)

The oligonucleotide set of claim 13, wherein the detectable label is a fluorescence marker.

### Claim 22

A kit for the detection of the pmpA gene of Chlamydia trachomatis in a biological sample comprising:
at least one oligonucleotide probe that is detectably labeled and has a nucleotide sequence length of about 10 to about 50, and at least two oligonucleotide primers, each of which has a nucleotide sequence length of about 10 to about 150,
wherein the probes and primers target the nucleotides of SEQ ID NO:2 at the location between about base pairs 1835-2176 on the pmpA gene;
wherein the at least one probe comprises a sequence selected from the group consisting of SEQ ID NO:12, SEQ ID NO:15 and oligonucleotide sequences that are at least 70% homologous to SEQ ID NO:12, and SEQ ID NO:15 and the at least two primers comprise oligonucleotide sequences selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:16 and oligonucleotide sequences that are at least 70% homologous to SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:16.

### Claim 23 (depends on 22)

The kit of claim 22, wherein the at least one probe comprises an oligonucleotide sequence selected from the group consisting of SEQ ID NO:12, SEQ ID NO:15 and oligonucleotide sequences that are at least 80% homologous to SEQ ID NO:12 and SEQ ID NO:15.

### Claim 24 (depends on 22)

The kit of claim 22, wherein the at least one probe comprises a oligonucleotide sequence selected from the group consisting of SEQ ID NO:12, SEQ ID NO:15, and oligonucleotide sequences that are at least 90% homologous to SEQ ID NO:12 and SEQ ID NO:15.

### Claim 25 (depends on 22)

The kit of claim 22, wherein the at least two primers comprises oligonucleotide sequences selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:16, and oligonucleotide sequences that are at least 80% homologous to SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:16.

### Claim 26 (depends on 22)

The kit of claim 22, wherein the at least two primers comprises oligonucleotide sequences selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:16, and oligonucleotide sequences that are at least 90% homologous to SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:16.

### Claim 27 (depends on 22)

The kit of claim 22, wherein the oligonucleotide set is selected from the group consisting of a first oligonucleotide set comprising oligonucleotide primers having an oligonucleotide sequence comprising SEQ ID NO:10 and SEQ ID NO:11 and an oligonucleotide probe having an oligonucleotide sequence comprising SEQ ID NO:12, a second oligonucleotide set comprising oligonucleotide primers having an oligonucleotide sequence comprising SEQ ID NO:13 and SEQ ID NO:14 and an oligonucleotide probe having an oligonucleotide sequence comprising SEQ ID NO:15 and a third oligonucleotide set comprising oligonucleotide primers having an oligonucleotide sequence comprising SEQ ID NO:13 and SEQ ID NO:16 and an oligonucleotide probe having an oligonucleotide sequence comprising SEQ ID NO:15.

### Claim 28 (depends on 22)

The kit of claim 22, wherein the at least two primers are selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, and oligonucleotide sequences that are at least 70% homologous to SEQ ID NO:10 and SEQ ID NO:11; and the at least one probe is selected from the group consisting of SEQ ID No:12 and oligonucleotide sequences that are at least 70% homologous to SEQ ID NO:12.

### Claim 29 (depends on 28)

The kit of claim 28, wherein the oligonucleotide primers consist of SEQ ID NO:10 and SEQ ID NO:11, and the oligonucleotide probe consists of SEQ ID NO:12.

### Claim 30 (depends on 22)

The kit of claim 22, wherein the primers and probes target the nucleotides of SEQ ID NO:2 at the location between about base pairs 1966-2073 of the pmpA gene.

### Claim 31 (depends on 22)

The kit of claim 22, wherein the detectable label is fluorescence marker.

### Claim 32 (depends on 22)

The kit of claim 22, wherein the primer and probes are provided in liquid or dried format.

### Claim 33 (depends on 22)

The kit of claim 22, further comprising reagents for performing polymerase chain reaction.

### Claim 34

A method of detecting Chlamydia trachomatis in a biological comprising:
obtaining a biological sample suspected of containing Chlamydia trachomatis;
mixing the biological sample with a buffer comprising a non-ionic detergent and optionally an organic solvent;
heating the biological sample mixed with the buffer at a temperature of about 85° C. to about 99° C. to lyse the Chlamydia trachomatis; and,
performing a polymerase chain reaction to detect the presence of Chlamydia trachomatis in the biological sample.
